ImmunOs Therapeutics AG Secures $11 Million in Series C Funding for Innovative Immunotherapy Development

ImmunOs Therapeutics AG is thrilled to announce the successful completion of a funding round that raised an impressive $11 million, propelling the company toward further advancements in the development of pioneering immunotherapies. Specializing in harnessing the innate immune system, ImmunOs Therapeutics is dedicated to transforming treatment paradigms for patients with cancer and autoimmune diseases. The newly acquired funds will accelerate the progression of its innovative therapies, particularly the lead program iosH2, which is set to enter Phase 1 clinical studies. iosH2 is a cutting-edge multi-functional fusion protein designed to inhibit specific leukocyte immunoglobulin-like receptors (LILRB), facilitating robust anti-tumor responses across various cancer types. This groundbreaking approach not only directly combats tumors but also works to remodel the tumor microenvironment, boosting the effectiveness of existing immunotherapies when combined with checkpoint inhibitors such as CTLA-4, PD-1, PD-L1, and CD47, as well as costimulatory agonists like 4-1BB. The funds will not only advance drug development but will also enable the expansion of the company’s scientific capabilities and resources. This strategic investment marks a critical step in ImmunOs Therapeutics’ mission to deliver the next generation of immunomodulatory proteins that can fundamentally improve treatment outcomes for patients battling life-threatening diseases. As we move forward, we remain committed to innovation and collaboration, driving forward the global fight against cancer and autoimmune challenges.